Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines

Competing interests

AM, consultant activity for Attralus, BioMarin Pharmaceutical, Bristol Myers Squibb, Cytokinetics, Eidos, Ionis, Pfizer and Lexicon Pharmaceuticals, Inc. and grants/contracts from Pfizer, Ionis, Cytokinetics and Attralus; MSM reports consultant activity for Cytokinetics, BioMarin Pharmaceutical Inc., Edgewise, Imbria; the other authors have no relevant conflicts of interest to disclose.

Comments (0)

No login
gif